• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

驱动蛋白纺锤体蛋白抑制剂作为抗癌药物的研究进展

Progress on kinesin spindle protein inhibitors as anti-cancer agents.

作者信息

Zhang Yingjie, Xu Wenfang

机构信息

Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, China.

出版信息

Anticancer Agents Med Chem. 2008 Aug;8(6):698-704.

PMID:18690830
Abstract

The kinesin spindle protein (KSP, also known as Hs Eg5) plays an essential part in the proper separation of spindle poles and the correct formation of bipolar mitotic spindle during mitosis. Inhibition of this protein results in cells apoptosis followed by mitotic arrest and the formation of characteristic monoaster spindles. Compared with the traditional chemotherapeutic agents (taxanes, vinca alkaloids), KSP inhibitors (KSPi) will not lead to the neuropathic side effects, so KSP has become a novel and an attractive anticancer target. Accordingly, more and more interest has been focused on the development of high effective and selective KSPi. This review will focus on some kinds of KSPi on the basis of introducing structure and function of KSP.

摘要

驱动蛋白纺锤体蛋白(KSP,也称为Hs Eg5)在有丝分裂过程中纺锤体极的正确分离和双极有丝分裂纺锤体的正确形成中起着至关重要的作用。抑制这种蛋白质会导致细胞凋亡,随后发生有丝分裂停滞并形成特征性的单星纺锤体。与传统化疗药物(紫杉烷类、长春花生物碱)相比,KSP抑制剂(KSPi)不会导致神经病变副作用,因此KSP已成为一个新的且有吸引力的抗癌靶点。相应地,越来越多的关注集中在开发高效且选择性的KSPi上。本综述将在介绍KSP的结构和功能的基础上,重点关注某些种类的KSPi。

相似文献

1
Progress on kinesin spindle protein inhibitors as anti-cancer agents.驱动蛋白纺锤体蛋白抑制剂作为抗癌药物的研究进展
Anticancer Agents Med Chem. 2008 Aug;8(6):698-704.
2
Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.基于受体-配体相互作用的虚拟筛选新型 Eg5/驱动蛋白纺锤体蛋白抑制剂。
J Med Chem. 2012 Mar 22;55(6):2561-73. doi: 10.1021/jm201290v. Epub 2012 Mar 1.
3
Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP.人有丝分裂驱动蛋白KSP选择性ATP竞争性抑制剂的发现及生化特性研究
Arch Biochem Biophys. 2008 Jan 15;469(2):220-31. doi: 10.1016/j.abb.2007.10.016. Epub 2007 Nov 1.
4
Mechanism of inhibition of human KSP by ispinesib.艾司西匹宁对人KSP的抑制机制。
Biochemistry. 2008 Mar 18;47(11):3576-85. doi: 10.1021/bi702061g. Epub 2008 Feb 22.
5
Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.核苷酸与抑制剂结合至野生型和耐ispsinesib形式的人驱动蛋白纺锤体蛋白的热力学
Biochemistry. 2009 Nov 24;48(46):11045-55. doi: 10.1021/bi900946r.
6
KSP inhibitors as antimitotic agents.KSP抑制剂作为抗有丝分裂剂。
Curr Top Med Chem. 2014;14(20):2286-311. doi: 10.2174/1568026614666141130095532.
7
Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition.莫那可林对人KSP的抑制机制:动力学分析及离子强度对KSP抑制作用的见解
Biochemistry. 2004 Dec 7;43(48):15258-66. doi: 10.1021/bi048282t.
8
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.二氢嘧啶类抑制 Eg5 的结构基础:抗有丝分裂抑制剂恩曲他滨、二甲烯氟苯及氟他胺的立体选择性。
J Med Chem. 2010 Aug 12;53(15):5676-83. doi: 10.1021/jm100421n.
9
Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.发现驱动蛋白纺锤体蛋白(KSP)的别构抑制剂用于治疗紫杉醇耐药性癌症:MK-0731 及其类似物。
Anticancer Agents Med Chem. 2010 Nov 1;10(9):697-712. doi: 10.2174/187152010794479807.
10
Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.驱动蛋白纺锤体蛋白(KSP)抑制剂。第1部分:3,5 - 二芳基 - 4,5 - 二氢吡唑作为有丝分裂驱动蛋白KSP的强效和选择性抑制剂的发现。
Bioorg Med Chem Lett. 2005 Apr 15;15(8):2041-5. doi: 10.1016/j.bmcl.2005.02.055.

引用本文的文献

1
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.小核酸疗法全景:作为下一代药物从实验室走向临床
Signal Transduct Target Ther. 2025 Mar 10;10(1):73. doi: 10.1038/s41392-024-02112-8.
2
The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma.KSP 抑制剂在胆管癌临床前模型中的治疗效果。
Cell Death Dis. 2022 Sep 19;13(9):799. doi: 10.1038/s41419-022-05247-0.
3
Identification of candidate biomarkers correlated with the pathogenesis and prognosis of breast cancer via integrated bioinformatics analysis.
通过综合生物信息学分析鉴定与乳腺癌发病机制和预后相关的候选生物标志物。
Medicine (Baltimore). 2020 Dec 4;99(49):e23153. doi: 10.1097/MD.0000000000023153.
4
High Eg5 expression predicts poor prognosis in breast cancer.高Eg5表达预示着乳腺癌的预后不良。
Oncotarget. 2017 Jul 10;8(37):62208-62216. doi: 10.18632/oncotarget.19215. eCollection 2017 Sep 22.
5
KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL.KSP抑制剂SB743921通过调节p53、Bcl-2和DTL来抑制乳腺癌细胞的生长并诱导其凋亡。
Anticancer Drugs. 2016 Oct;27(9):863-72. doi: 10.1097/CAD.0000000000000402.
6
Discovery of Novel Allosteric Eg5 Inhibitors Through Structure-Based Virtual Screening.通过基于结构的虚拟筛选发现新型别构Eg5抑制剂。
Chem Biol Drug Des. 2016 Aug;88(2):178-87. doi: 10.1111/cbdd.12744. Epub 2016 Mar 6.
7
Clotrimazole as a Cancer Drug: A Short Review.克霉唑作为一种抗癌药物:简短综述。
Med Chem (Los Angeles). 2014;4(11):722-724. doi: 10.4172/2161-0444.1000219.
8
Downregulation of Kinesin spindle protein inhibits proliferation, induces apoptosis and increases chemosensitivity in hepatocellular carcinoma cells.驱动蛋白纺锤体蛋白的下调抑制肝癌细胞的增殖,诱导其凋亡并增加其化学敏感性。
Iran Biomed J. 2015;19(1):1-16. doi: 10.6091/ibj.1386.2014.
9
Cellular delivery and photochemical activation of antisense agents through a nucleobase caging strategy.通过碱基封闭策略实现反义试剂的细胞传递和光化学激活。
ACS Chem Biol. 2013 Oct 18;8(10):2272-82. doi: 10.1021/cb400293e. Epub 2013 Aug 19.
10
p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells.p63 表达与膀胱癌细胞对 Eg5 抑制剂 ZD4877 的敏感性相关。
Cancer Biol Ther. 2012 May;13(7):477-86. doi: 10.4161/cbt.19590. Epub 2012 May 1.